Tele-Sleep OSA: Clinical Effectiveness, Implementation, and Economic Impact of Telehealth Care for Obstructive Sleep Apnea in the Military Health System
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 160
- 试验地点
- 4
- 主要终点
- Apnea-Hypopnea Index (AHI): Assesses OSA severity via events/hour from diagnostic testing.
研究概览
简要总结
The long-term goal of this research is to improve military health and operational readiness among military service members with sleep disorders. The overall objective of the current study is to 1) determine the clinical effectiveness (non-inferiority) and cost-effectiveness of OSA telehealth care, including a human sleep navigator (vs private sector care), and 2) to perform a formative evaluation of the implementation of the OSA telehealth care intervention within the National Capitol Region (NCR) market. The central hypothesis is that OSA telehealth care including a human sleep navigator is clinically non-inferior to private sector care and also more cost-effective than private sector care. The investigators plan to achieve the objectives via these 3 Specific Aims: Specific Aim 1: To determine the clinical effectiveness (non-inferiority) of OSA telehealth care, relative to private sector care. Hypothesis 1a: Relative to private sector care, OSA telehealth care is non-inferior for achieving PAP adherence (primary endpoint).
Hypothesis 1b: Relative to private sector care, OSA telehealth care is non-inferior for reducing OSA symptoms and for patient satisfaction (secondary endpoints).
Specific Aim 2: To engage participants via qualitative focus groups and conduct a formative evaluation of the implementation of the OSA telehealth care intervention, using a standardized approach based on the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework.
Specific Aim 3: To perform a cost-effectiveness analysis of OSA telehealth care from the DHA perspective.
Hypothesis 3: Relative to private sector care, OSA telehealth care is more cost-effective.
详细描述
Obstructive sleep apnea (OSA) is a common and costly chronic medical condition that impacts approximately 27% of men and 9% of women in the U.S. and approximately 936 million adults worldwide. Within the military health system (MHS), the prevalence of OSA is approximately 51.2% and rapidly increasing (e.g., from 11 to 333 per 10,000 ADSMs between the years of 2005 and 2019).3 OSA is characterized by repetitive breathing pauses throughout the night, each lasting a minimum of ten seconds, resulting in blood oxygen desaturations and associated cortical arousals during sleep, as the brain tries harder to breathe and obtain needed oxygen. OSA is associated with worsened medical (cardiovascular disease, stroke, metabolic syndromes [including Type 2 diabetes], and premature death) and mental health (depression, anxiety, traumatic stress, substance misuse) outcomes, and worsened quality of life. Beyond these health consequences, OSA is also associated with dramatically increased costs, including both direct treatment costs as well as indirect costs such as increased risk for motor vehicle crash, lost workplace productivity, and costly workplace accidents and errors. The adverse impact of OSA on readiness and deployability for the Armed Services is also extremely costly. Within the context of the MHS, all direct and most indirect costs are borne by the Defense Health Agency (DHA).
The most common treatment for OSA is positive airway pressure (PAP) therapy. PAP involves a small mask that fits over the nose (or mouth and nose) and gently blows air, creating a pneumatic splint that holds the airway open during sleep. When used as prescribed, PAP results in myriad health benefits, including dramatic reductions in sleepiness and risks associated with sleepiness (e.g., motor vehicle crash), as well as improvements in health-related quality of life (HrQOL), memory, blood pressure, other mental and physical health benefits with high military relevance, and reduced costs.
Unfortunately, despite the high prevalence and well-documented consequences of OSA in the MHS, few studies have examined the impact of OSA treatment on clinical and economic outcomes in the MHS.
Within the MHS there is a gross shortage of trained sleep specialist providers and accredited sleep centers. Thus, the demand for sleep medicine specialty care greatly exceeds available supply. As a result, most MHS beneficiaries receive sleep medicine specialty care through the civilian network and TRICARE contracted providers (i.e., standard purchased care). A typical course of OSA private sector care includes multiple billed face-to-face encounters with a sleep medicine physician, in-lab sleep studies, and provision of PAP equipment billed through various third-party durable medical equipment (DME) providers that are also contracted with TRICARE. Given very high volumes, the costs of standard purchased care borne by the DHA are substantial, and quality is variable. Further, patients often struggle to navigate this complex care process that involves multiple providers with suboptimal care coordination (e.g., primary care, specialty care, DME). Optimizing the approach to OSA care is a vital consideration.
In non-MHS samples, OSA telehealth care has demonstrated clinical non-inferiority and enhanced cost-effectiveness relative to OSA in-person care, while also increasing access to care. For example, home sleep apnea testing (HSAT) and auto-titrating positive airway pressure (APAP) have been extensively validated as viable alternatives to attended in-lab diagnostic sleep studies (i.e., polysomnogram [PSG]) and attended in lab therapeutic sleep studies (i.e., manual PAP titration), respectively. In addition, several studies have highlighted the potential role of non-sleep specialists - including non-physician providers - to increase access to OSA care and deliver high quality OSA care. These findings are especially notable given both the major "virtual first" DHA initiative as well as the DHA Quadruple Aim: improved health readiness, better health, better care, and lower cost. Even so, there remain important gaps in knowledge, particularly from the DHA perspective.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-64 years
- •ADFM or DEERS beneficiary
- •Enrolled in any TRICARE (Prime, Standard, or Extra)
- •Deferred to private sector care (i.e., local TRICARE network) for OSA care
- •Newly diagnosed with OSA (AHI>5)
- •Access to smartphone, desktop, laptop, or tablet computer
排除标准
- •History of prior OSA testing, diagnosis, or care
- •Contraindication for home sleep apnea testing, based on established AASM criteria
- •History of or high-risk for organic sleep disorders other than OSA (e.g., REM behavior disorder, obesity hypoventilation syndrome)
- •Active alcohol or substance dependence
- •Severe sleepiness (Epworth Sleepiness Scale [ESS]>18, or clinician judgment)
- •Pending permanent family change of station (PCS) within 6 months
- •Active-duty military service members (ADSM)
- •Untreated major medical or psychiatric illness
- •Pursuit of non-PAP treatment for OSA
结局指标
主要结局
Apnea-Hypopnea Index (AHI): Assesses OSA severity via events/hour from diagnostic testing.
时间窗: Participants are actively involved in the study for at least 90 days (approximately 3 months) following the initiation of PAP therapy.
Unit: Events/hour Scale: Continuous; higher values = more severe outcome
Oxygen Desaturation Metrics: Reports oxygen nadir (%) and % of sleep time with saturation <90%.
时间窗: Participants are actively involved in the study for at least 90 days (approximately 3 months) following the initiation of PAP therapy
Units: Nadir (%), Time \<90% (% of total sleep time) Scale: Continuous; lower nadir = worse outcome, higher time \<90% = worse outcome
Positive Airway Pressure (PAP) Adherence
时间窗: Participants are actively involved in the study for at least 90 days (approximately 3 months) following the initiation of PAP therapy.
Includes treatment start date and usage (hours/night, % nights/week). Units: Start date; usage = hours/night, % nights/week Scale: Hours/night (min 0), % nights/week (0-100%); higher values = better outcome
PSQI: Pittsburgh Sleep Quality Index
时间窗: Participants are actively involved in the study for at least 90 days (approximately 3 months) following the initiation of PAP therapy
Assesses sleep quality (0-21); higher = poorer sleep. Scale: 0 - no difficulty and 21 indicating severe difficulties
ISI: Insomnia Severity Index
时间窗: Participants are actively involved in the study for at least 90 days (approximately 3 months) following the initiation of PAP therapy
Rates insomnia severity (0-28); higher = worse. Scale: 15-21 moderate insomnia, 22-28 severe insomnia.
ESS - Epworth Sleepiness Scale
时间窗: Participants are actively involved in the study for at least 90 days (approximately 3 months) following the initiation of PAP therapy
Assesses daytime sleepiness (0-24); higher = worse. Scale: 11-12 mild, 13-15 moderate, 16-24 excessive sleepiness.
FOSQ: Functional Outcomes of Sleep Questionnaire
时间窗: Participants are actively involved in the study for at least 90 days (approximately 3 months) following the initiation of PAP therapy
Evaluates OSA-related functional impact; higher scores = better functioning. Scale: 4 - no difficulty, 3 - yes, a little difficulty, 2 - yes, moderate difficulty, 1 - yes, extreme difficulty.
SF-12 - Short-form 12
时间窗: Participants are actively involved in the study for at least 90 days (approximately 3 months) following the initiation of PAP therapy.
Evaluates general health-related quality of life. Scale: The scoring yields two summary measures: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Interpretation of Scores: Norm-based scoring system will be used to interpret PCS and MCS scores, with a mean of 50 and a standard deviation of 10 in the general population. Scores above 50 indicate a better-than-average health-while scores below 50 suggest below-average health.
PHQ-8 - Patient Health Questionnaire 8
时间窗: Participants are actively involved in the study for at least 90 days (approximately 3 months) following the initiation of PAP therapy.
PHQ-8: Measures depressive symptoms (0-24); higher = worse. Scale: 0-4 no significant depression, 5-9 mild depressive symptoms, 10-14 moderate depressive symptoms, 15-19 moderately severe depressive symptoms, 20-24 severe depressive symptoms.
GAD-7: Generalized Anxiety Disorder - 7
时间窗: Participants are actively involved in the study for at least 90 days (approximately 3 months) following the initiation of PAP therapy
Evaluates anxiety symptoms (0-21); higher = worse anxiety severity. Scale: 0-4 minimal anxiety, 5-9 mild anxiety, 10-14 moderate anxiety, 15-21 severe anxiety
PCL-5 - PTSD Checklist for DSM-5
时间窗: Participants are actively involved in the study for at least 90 days (approximately 3 months) following the initiation of PAP therapy.
Evaluates trauma symptoms. Scale: 0-20 minimal symptoms, 21-40 mild symptoms, 41-60 moderate symptoms, 61-80 severe symptoms.
WPAI: Work Productivity and Activity Impairment Questionnaire
时间窗: Participants are actively involved in the study for at least 90 days (approximately 3 months) following the initiation of PAP therapy
Measures impairment in work/daily activities. Determines impact in percentages on absenteeism, presenteeism, overall work impairment, and activity impairment. higher %= greater impact. Scale: (0-100%), Higher scores indicate greater impairment and less productivity
RE-AIM: Reach, Effectiveness, Adoption, Implementation, Maintenance
时间窗: Participants are actively involved in the study for at least 90 days (approximately 3 months) following the initiation of PAP therapy.
Modified questionnaire to measure patient satisfaction. Formative evaluation
Health Care Utilization
时间窗: Participants are actively involved in the study for at least 90 days (approximately 3 months) following the initiation of PAP therapy.
Measures quantity healthcare services including dates and types of encounters, OSA diagnostic testing, and provision of PAP machines and supplies.
次要结局
未报告次要终点